Product image of Maviret (Glecaprevir, Pibrentasvir) supplied by GNH India

Maviret

Active Ingredient:
Glecaprevir, Pibrentasvir
Origin:
EU

Maviret (Glecaprevir, Pibrentasvir)

Glecaprevir/pibrentasvir, the active ingredient in Maviret, is a NS3/4A protease inhibitor and NS5A inhibitor presented as a glecaprevir 300 mg / pibrentasvir 120 mg tablet for oral use. It treats chronic hepatitis C virus infection across genotypes 1‑6 in adults, including those with compensated cirrhosis, by blocking key steps in viral replication and assembly.

GNH India supplies Maviret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Manufacturer / TM Owner

Abbvie Deutschland Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maviret is indicated for the treatment of chronic hepatitis C virus infection, a viral liver disease.

  • Chronic hepatitis C (genotypes 1‑6): achieves sustained virologic response in the majority of adult patients.
  • Compensated cirrhosis due to hepatitis C: enables viral clearance while preserving liver function.
  • Treatment‑experienced adults: provides an effective pan‑genotypic option after prior therapy.

How It Works

  • Glecaprevir binds to the HCV NS3/4A protease, preventing cleavage of the viral polyprotein and halting replication. Pibrentasvir attaches to the NS5A replication complex, disrupting RNA replication and virion assembly. The combined inhibition blocks two essential steps in the hepatitis C virus life cycle, leading to rapid decline of viral load.

Side Effects

Maviret may cause adverse reactions; reported events vary in frequency.

Common Side Effects

  • Headache
  • Fatigue
  • Nausea
  • Diarrhea
  • Abdominal pain
  • Itching (pruritus)

Serious or Rare Side Effects

  • Elevated liver enzymes or hepatic decompensation
  • Severe allergic reactions such as rash or angioedema
  • Anemia
  • Jaundice or hepatic failure
  • Significant fatigue or weakness

Precautions & Warnings

When prescribing Maviret, consider the following precautions to ensure safe use.

  • Assess liver function: baseline hepatic enzymes and fibrosis stage should be evaluated.
  • Avoid in severe hepatic impairment: not recommended for Child‑Pugh B or C patients.
  • Monitor for drug‑drug interactions: review all concomitant medications.
  • Pregnancy and breastfeeding: safety not established; avoid unless benefit outweighs risk.
  • Renal function: monitor in severe renal impairment, although dose adjustment is not required.
  • Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Avoid Interactions

Maviret has a potential for drug‑drug interactions; review concomitant medicines before initiating therapy.

Major Interactions (Avoid)

  • Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort): markedly reduce drug exposure.
  • Co‑administration with certain HCV NS5A inhibitors not approved together: may increase toxicity.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A inducers (e.g., efavirenz): may lower efficacy.
  • P‑glycoprotein inhibitors (e.g., itraconazole, ketoconazole): can increase plasma levels.
  • Acid‑reducing agents (e.g., omeprazole, ranitidine): may affect absorption.
  • Statins (simvastatin, lovastatin): increased risk of myopathy.
  • Certain antiretrovirals (atazanavir, darunavir): may require dose adjustment.

Frequently Asked Questions

Maviret is prescribed for the treatment of chronic hepatitis C virus infection in adults, covering all major genotypes (1‑6). It is also indicated for patients who have compensated cirrhosis, helping to achieve viral clearance and improve liver health.

The combination contains two agents: Glecaprevir blocks the HCV NS3/4A protease, stopping viral polyprotein processing, while Pibrentasvir inhibits the NS5A replication complex, disrupting RNA synthesis and virus assembly. Together they halt viral replication at two critical stages.

The prescribed dose of Maviret is determined by the treating physician based on the patient’s genotype, liver condition, and prior treatment history. Typically, a single tablet containing glecaprevir 300 mg and pibrentasvir 120 mg is taken once daily for a defined treatment period.

Safety data for Glecaprevir/Pibrentasvir in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

To order Maviret, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maviret offers a pan‑genotypic regimen in a single daily tablet, which can simplify therapy compared with multi‑tablet combinations such as Sofosbuvir/Velpatasvir. Its high barrier to resistance and suitability for patients with compensated cirrhosis make it a competitive option, though individual choice depends on genotype, prior therapy, and comorbidities.

Maviret tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture. Keep the product out of direct sunlight and away from excessive heat or humidity to maintain potency.

Maviret is taken orally as a whole tablet with or without food. Patients should swallow the tablet whole, not chew or split it, and follow the dosing schedule prescribed by their healthcare provider.

Serious risks include hepatic decompensation or severe liver enzyme elevations, especially in patients with underlying liver disease, as well as rare but severe allergic reactions such as rash, angioedema, or anaphylaxis. Prompt medical attention is required if any of these occur.

Maviret is contraindicated in patients with severe hepatic impairment (Child‑Pugh B or C) and in individuals with known hypersensitivity to Glecaprevir, Pibrentasvir, or any tablet components. Caution is also advised for pregnant or nursing women, and for those taking strong CYP3A inducers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Glecaprevir, Pibrentasvir

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT